All In Biotech

Drug Trial Radar · NCT07281495

Taldefgrobep Alfa in Adults With Overweight and Obesity

A Phase 2b, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study With Open-Label Extension to Assess the Efficacy, Safety, and Pharmacokinetics of Subcutaneously Administered Taldefgrobep Alfa in Adults Living With Overweight and Obesity

Last checked: Nov 19, 2026Latest source record: Mar 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 150 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

150

Planned (sponsor's estimate)

Start

Nov 24, 2025

Primary completion

Sep 2026

Study completion Sep 2026

Sponsor

Lead sponsor
Biohaven Therapeutics Ltd.Industry
Sponsor type
Industry
First posted
Dec 15, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, randomized, double-blind, placebo-controlled, multiple dose study to evaluate the efficacy, safety, and tolerability of taldefgrobep alfa in adults with overweight and obesity, with an open-label extension.

Conditions

  • Obesity
  • Overweight

Interventions

  • Taldefgrobep AlfaDrug

    Subcutaneous injection administered once each week

  • PlaceboDrug

    Subcutaneous injection (matching placebo) administered once each week

  • Taldefgrobep AlfaDrug

    Subcutaneous injection administered once every 4 weeks

  • PlaceboDrug

    Subcutaneous injection (matching placebo) administered once every 4 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent change in total body weight from Baseline to Week 24Time frame: Baseline to Week 24

Locations

20 sites in 1 country. Site status is shown where the registry gives one.

  • Site-001

    Chula Vista, California

  • Site-014

    Montclair, California

  • Site-011

    Sacramento, California

  • Site-018

    Tustin, California

  • Site-020

    Orlando, Florida

  • Site-008

    Palm Springs, Florida

  • Site-015

    St. Petersburg, Florida

  • Site-007

    Chicago, Illinois

  • Site-016

    Indianapolis, Indiana

  • Site-010

    Baton Rouge, Louisiana

  • Site-009

    Metairie, Louisiana

  • Site-006

    City of Saint Peters, Missouri

  • Site-003

    Springfield, Missouri

  • Site-019

    Monroe, North Carolina

  • Site-002

    Fargo, North Dakota

  • Site-017

    North Charleston, South Carolina

  • Site-005

    Austin, Texas

  • Site-012

    McKinney, Texas

  • Site-013

    San Antonio, Texas

  • Site-004

    Arlington, Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.